vs

Side-by-side financial comparison of Advantage Solutions Inc. (ADV) and Steris (STE). Click either name above to swap in a different company.

Steris is the larger business by last-quarter revenue ($1.5B vs $932.1M, roughly 1.6× Advantage Solutions Inc.). Steris runs the higher net margin — 12.9% vs -17.4%, a 30.2% gap on every dollar of revenue. On growth, Steris posted the faster year-over-year revenue change (9.2% vs 4.5%). Steris produced more free cash flow last quarter ($199.5M vs $23.4M). Over the past eight quarters, Steris's revenue compounded faster (15.8% CAGR vs 4.0%).

LexisNexis Risk Solutions is a global data and analytics company that provides data and technology services, analytics, predictive insights, and fraud prevention for a wide range of industries. It is headquartered in Alpharetta, Georgia, and has offices throughout the U.S. and in Australia, Brazil, China, France, Hong Kong, India, Ireland, Israel, the Philippines, and the United Kingdom.

Steris plc is an American-Irish-based medical equipment company specializing in sterilization and surgical products for the US healthcare system. Steris is operationally headquartered in Mentor, Ohio, and has been legally registered in Dublin, Ireland, for tax purposes since 2018. Previously the company was registered in the United Kingdom from 2014 to 2018.

ADV vs STE — Head-to-Head

Bigger by revenue
STE
STE
1.6× larger
STE
$1.5B
$932.1M
ADV
Growing faster (revenue YoY)
STE
STE
+4.7% gap
STE
9.2%
4.5%
ADV
Higher net margin
STE
STE
30.2% more per $
STE
12.9%
-17.4%
ADV
More free cash flow
STE
STE
$176.1M more FCF
STE
$199.5M
$23.4M
ADV
Faster 2-yr revenue CAGR
STE
STE
Annualised
STE
15.8%
4.0%
ADV

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
ADV
ADV
STE
STE
Revenue
$932.1M
$1.5B
Net Profit
$-161.7M
$192.9M
Gross Margin
43.8%
Operating Margin
-17.4%
18.3%
Net Margin
-17.4%
12.9%
Revenue YoY
4.5%
9.2%
Net Profit YoY
9.2%
11.2%
EPS (diluted)
$1.96

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ADV
ADV
STE
STE
Q4 25
$932.1M
$1.5B
Q3 25
$915.0M
$1.5B
Q2 25
$873.7M
$1.4B
Q1 25
$821.8M
$1.5B
Q4 24
$892.3M
$1.4B
Q3 24
$939.3M
$1.3B
Q2 24
$873.4M
$1.3B
Q1 24
$861.4M
$1.1B
Net Profit
ADV
ADV
STE
STE
Q4 25
$-161.7M
$192.9M
Q3 25
$20.6M
$191.9M
Q2 25
$-30.4M
$177.4M
Q1 25
$-56.1M
$145.7M
Q4 24
$-178.0M
$173.5M
Q3 24
$-42.8M
$150.0M
Q2 24
$-100.8M
$145.4M
Q1 24
$-5.3M
$-1.4M
Gross Margin
ADV
ADV
STE
STE
Q4 25
43.8%
Q3 25
44.2%
Q2 25
45.1%
Q1 25
43.3%
Q4 24
44.5%
Q3 24
43.6%
Q2 24
44.7%
Q1 24
40.2%
Operating Margin
ADV
ADV
STE
STE
Q4 25
-17.4%
18.3%
Q3 25
4.4%
18.2%
Q2 25
1.1%
17.7%
Q1 25
-1.8%
14.6%
Q4 24
-19.1%
17.9%
Q3 24
-0.3%
16.5%
Q2 24
-10.4%
14.5%
Q1 24
-3.5%
22.0%
Net Margin
ADV
ADV
STE
STE
Q4 25
-17.4%
12.9%
Q3 25
2.2%
13.1%
Q2 25
-3.5%
12.8%
Q1 25
-6.8%
9.8%
Q4 24
-20.0%
12.7%
Q3 24
-4.6%
11.3%
Q2 24
-11.5%
11.4%
Q1 24
-0.6%
-0.1%
EPS (diluted)
ADV
ADV
STE
STE
Q4 25
$1.96
Q3 25
$1.94
Q2 25
$1.79
Q1 25
$1.48
Q4 24
$1.75
Q3 24
$-0.13
$1.51
Q2 24
$-0.31
$1.46
Q1 24
$-0.02
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ADV
ADV
STE
STE
Cash + ST InvestmentsLiquidity on hand
$240.8M
$423.7M
Total DebtLower is stronger
$1.7B
$1.9B
Stockholders' EquityBook value
$554.0M
$7.2B
Total Assets
$2.8B
$10.6B
Debt / EquityLower = less leverage
3.05×
0.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ADV
ADV
STE
STE
Q4 25
$240.8M
$423.7M
Q3 25
$201.1M
$319.2M
Q2 25
$102.9M
$279.7M
Q1 25
$121.1M
$171.7M
Q4 24
$205.2M
$155.2M
Q3 24
$196.1M
$172.2M
Q2 24
$154.0M
$198.3M
Q1 24
$112.3M
$207.0M
Total Debt
ADV
ADV
STE
STE
Q4 25
$1.7B
$1.9B
Q3 25
$1.9B
Q2 25
$1.9B
Q1 25
$1.9B
Q4 24
$1.7B
$2.0B
Q3 24
$2.2B
Q2 24
$2.2B
Q1 24
$3.1B
Stockholders' Equity
ADV
ADV
STE
STE
Q4 25
$554.0M
$7.2B
Q3 25
$708.5M
$7.0B
Q2 25
$683.6M
$7.0B
Q1 25
$695.6M
$6.6B
Q4 24
$748.7M
$6.4B
Q3 24
$932.5M
$6.6B
Q2 24
$973.7M
$6.4B
Q1 24
$1.1B
$6.3B
Total Assets
ADV
ADV
STE
STE
Q4 25
$2.8B
$10.6B
Q3 25
$3.0B
$10.4B
Q2 25
$3.0B
$10.4B
Q1 25
$3.0B
$10.1B
Q4 24
$3.1B
$10.0B
Q3 24
$3.4B
$10.2B
Q2 24
$3.5B
$10.1B
Q1 24
$3.6B
$11.1B
Debt / Equity
ADV
ADV
STE
STE
Q4 25
3.05×
0.27×
Q3 25
0.27×
Q2 25
0.27×
Q1 25
0.29×
Q4 24
2.30×
0.32×
Q3 24
0.33×
Q2 24
0.35×
Q1 24
0.50×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ADV
ADV
STE
STE
Operating Cash FlowLast quarter
$45.6M
$298.2M
Free Cash FlowOCF − Capex
$23.4M
$199.5M
FCF MarginFCF / Revenue
2.5%
13.3%
Capex IntensityCapex / Revenue
2.4%
6.6%
Cash ConversionOCF / Net Profit
1.55×
TTM Free Cash FlowTrailing 4 quarters
$10.7M
$917.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ADV
ADV
STE
STE
Q4 25
$45.6M
$298.2M
Q3 25
$63.6M
$287.8M
Q2 25
$-8.1M
$420.0M
Q1 25
$-39.6M
$260.8M
Q4 24
$15.1M
$332.8M
Q3 24
$34.0M
$250.7M
Q2 24
$53.4M
$303.7M
Q1 24
$-9.4M
$254.8M
Free Cash Flow
ADV
ADV
STE
STE
Q4 25
$23.4M
$199.5M
Q3 25
$52.2M
$201.3M
Q2 25
$-10.2M
$326.4M
Q1 25
$-54.7M
$189.9M
Q4 24
$-27.4M
$243.6M
Q3 24
$8.6M
$148.8M
Q2 24
$43.8M
$195.7M
Q1 24
$-24.8M
$163.3M
FCF Margin
ADV
ADV
STE
STE
Q4 25
2.5%
13.3%
Q3 25
5.7%
13.8%
Q2 25
-1.2%
23.5%
Q1 25
-6.7%
12.8%
Q4 24
-3.1%
17.8%
Q3 24
0.9%
11.2%
Q2 24
5.0%
15.3%
Q1 24
-2.9%
14.6%
Capex Intensity
ADV
ADV
STE
STE
Q4 25
2.4%
6.6%
Q3 25
1.3%
5.9%
Q2 25
0.2%
6.7%
Q1 25
1.8%
4.8%
Q4 24
4.8%
6.5%
Q3 24
2.7%
7.7%
Q2 24
1.1%
8.4%
Q1 24
1.8%
8.2%
Cash Conversion
ADV
ADV
STE
STE
Q4 25
1.55×
Q3 25
3.09×
1.50×
Q2 25
2.37×
Q1 25
1.79×
Q4 24
1.92×
Q3 24
1.67×
Q2 24
2.09×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ADV
ADV

Experiential Services$395.9M42%
Branded Services$289.8M31%
Retailer Services$246.5M26%

STE
STE

Servicerevenues$404.7M27%
Consumablerevenues$387.1M26%
Applied Sterilization Technologies$286.6M19%
Capitalequipmentrevenues$272.1M18%
Life Science$145.8M10%

Related Comparisons